Antibody-Based Therapies for Emerging Infectious Diseases

Research output: Contribution to journalArticle

Abstract

In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.

Original languageEnglish (US)
Pages (from-to)200-208
Number of pages9
JournalEmerging Infectious Diseases
Volume2
Issue number3
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Emerging Communicable Diseases
Antibodies
Therapeutics
Serum
Anti-Infective Agents
Coinfection
Antibody Formation
Communicable Diseases
Immune Sera
Pharmacokinetics
Monoclonal Antibodies
Technology
Costs and Cost Analysis
Drug Therapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Microbiology (medical)

Cite this

Antibody-Based Therapies for Emerging Infectious Diseases. / Casadevall, Arturo.

In: Emerging Infectious Diseases, Vol. 2, No. 3, 07.1996, p. 200-208.

Research output: Contribution to journalArticle

@article{b9fa803fc3054665b6e179ee0b6f7c2c,
title = "Antibody-Based Therapies for Emerging Infectious Diseases",
abstract = "In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.",
author = "Arturo Casadevall",
year = "1996",
month = "7",
language = "English (US)",
volume = "2",
pages = "200--208",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "3",

}

TY - JOUR

T1 - Antibody-Based Therapies for Emerging Infectious Diseases

AU - Casadevall, Arturo

PY - 1996/7

Y1 - 1996/7

N2 - In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.

AB - In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.

UR - http://www.scopus.com/inward/record.url?scp=0030184441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030184441&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 200

EP - 208

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 3

ER -